Kyongbo Pharmaceutical Discloses 2025 Corporate Governance Report: Net Profit Plunges 96% and Lack of Dividend Predictability Highlights Shareholder Return Risks
Kyongbo Pharmaceutical (Chong Kun Dang Group affiliate) reported 2025 consolidated sales of 264.1B KRW (+10.7% YoY), operating profit of 3.5B KRW (-66.3%), and net profit of 0.18B KRW (-96.1%), a sharp decline in profitability. Separate payout ratio reached 656.6%, indicating excessive dividend relative to net income.
Governance: 10 out of 15 core indicators complied; 5 non-compliant including lack of dividend predictability, failure to notify dividend policy annually, board chair not independent, no cumulative voting, single-gender board (all male), no internal audit department, and no accounting/finance expert on audit.
Largest shareholder: Chong Kun Dang Holdings with 60.56% stake. Total shares: 23,906,860, par value 500 KRW. No capital changes.
Shareholder returns: Cash dividend of 50 KRW per share for the past three years (yield 0.6-0.8%), no share buybacks or cancellations. No formal dividend policy reduces predictability.
Board: 5 members (3 inside, 2 outside), all male, outside director ratio 40%. CEO succession policy established in 2025. No board committees (assets under 2 trillion KRW).
Audit: One full-time auditor (not accounting expert), no dedicated support team. External auditor: Ichon Accounting (periodic designation). Quarterly meetings without management.
Voluntary disclosure of value-up plan in March 2026 without board participation. Limited shareholder communication.
[AI Summary]The 96% plunge in 2025 net profit severely weakens Kyongbo's capacity to sustain dividends, while governance shortcomings like lack of dividend predictability may undermine investor confidence. However, there are no dilution or capital-raising events, and the stable control by Chong Kun Dang Group suggests long-term challenges rather than an immediate crisis.